Key result
Atorvastatin 10 mg daily reduces ADP-induced platelet aggregation in hypercholesterolemic patients with CAD.
Why the study?
The effect of atorvastatin on platelet aggregation in patients with coronary artery disease was not well characterized.
Does atorvastatin reduce platelet aggregation in hypercholesterolaemic patients with coronary artery disease?
Does atorvastatin reduce platelet aggregation in hypercholesterolaemic patients with coronary artery disease?
Atorvastatin 10 mg/day reduces ADP-induced platelet aggregation in patients with CAD, suggesting an additional pleiotropic anti-thrombotic benefit beyond lipid lowering.
Atorvastatin was associated with reduced ADP-induced platelet aggregation in CAD; leaves open clinical relevance and requires randomized confirmation.
BACKGROUND: Lipid-lowering therapy was shown to have several beneficial effects in patients with coronary artery disease (CAD). AIM: The objective of this study was to investigate the effect of atorvastatin on platelet aggregation in patients with CAD. METHODS: Twenty-five hypercholesterolaemic patients who had angiographically proven CAD and 16 normal subjects were enrolled. All patients received 10 mg/day atorvastatin for two months. Anti-platelet agents were discontinued 15 days prior to blood sampling at the beginning and at the end of the atorvastatin therapy. Aggregometric curves of the platelets in response to ADP, collagen and epinephrine were obtained using the aggregometry (turbidimetric) technique. RESULTS: In patients with CAD, total cholesterol (TC) and LDL cholesterol (LDL-C) basal levels were measured (230 +/- 49 mg/dl, 140 +/- 41 mg/dl, respectively). Following lipid-lowering therapy, TC and LDL-C decreased significantly (p < 0.05). The activation measurements of aggregometric curves decreased significantly compared with basal parameters in response to ADP but not in response to collagen and epinephrine. CONCLUSION: Lipid-lowering therapy with the HMG-CoA reductase inhibitor, atorvastatin, had a marked reduction effect on platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Tekten et al. (2004) studied coronary artery disease (n=41). Atorvastatin vs. Basal parameters was evaluated on Platelet aggregation in response to ADP, collagen and epinephrine. Atorvastatin 10 mg/day for two months significantly reduced platelet aggregation in response to ADP in hypercholesterolaemic patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: